Gastroenterology

Even those who checked three or four of the five items had some improvement in their risk.

Then there's the German Doc Study, led by Dr. Prudence Carr and published in Gastroenterology in 2018.

Each habit her team studied independently lowered the CRC colorectal cancer risk.

Not smoking, no or moderate alcohol intake, a healthy diet, physical activity, and a healthy body mass index.

And one of the most interesting parts of the research involves the intestine.

The 2008 Gastroenterology Study In a study published in Gastroenterology in 2008, Guillaume Dalmasso and colleagues investigated KPV in intestinal epithelial cells, immune cells, and two mouse models of colitis.

The study examined a transporter called PEPT1.

PEPT1 normally transports certain small peptides across cell membranes, particularly in the small intestine.

Two other lines of evidence I will mention.

One is case control studies, of which there have been two, one published in 2018 in Gastroenterology, one published in 2021 in the Journal of Hepatology.

The first one examined the association between receipt of surveillance data and HC-related mortality among patients with cirrhosis and found no association.

And the second one was in people with chronic hepatitis B, and it did find a strong protective effect of HCC surveillance.

Absolutely.

A major study published in the journal M Systems analyzed the gut biomes of 2,300 adults.

And they found that postmenopausal women trend toward much lower gut microbiome diversity.

Their microbial landscape actually shifts to look more like a man's microbiome.

But when they hit the perimenopause transition, that number jumps to 19.2%, and it stays elevated at 19% postmenopause.

And there is a proven physical bidirectional relationship between the gut and the brain.

I was looking at a 12-year population study from the journal Gut, showed that people with higher anxiety actually predicted the later development of functional gut disorders.

Yes, the connection is incredibly strong.

So I think that is absolutely worth noting.

However, what I would say is that there is a trial in the Gastroenterology Journal and that's by Singh and colleagues in 2025.

And it was a randomized double blind sham control trial across eight centers and people with IBS, irritable bowel syndrome, who were positive to at least one food on an 18-food IgG assay were assigned to either an antibody-guided elimination diet or just a sham diet for eight weeks.

And a sham is just a fake version of a treatment designed to look and feel identical to the real thing, so the participant can't tell what they got.